Published in
Oxford University Press, Clinical Infectious Diseases, 1(71), p. 207-210, 2019
DOI: 10.1093/cid/ciz991
Links
Tools
Clinical and Economic Impact of Implementing OVIVA Criteria on Patients With Bone and Joint Infections in Outpatient Parenteral Antimicrobial Therapy
Journal article published in 2019 by
Michael Marks,
Lucy C. K. Bell,
Imogen Jones,
Tommy Rampling 
,
Katharina Kranzer,
Stephen Morris-Jones,
Sarah Logan,
Gabriele Pollara
,
Katharina Kranzer,
Stephen Morris-Jones,
Sarah Logan,
Gabriele Pollara
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
AbstractThe OVIVA study demonstrated noninferiority for managing bone and joint infections (BJIs) with oral antibiotics. We report that 79.7% of OPAT patients being treated for BJIs at our center would be eligible for oral antibiotics, saving a median (IQR) 19.5 IV-antibiotic days (8.5–37) and GBP 1234 (569–2594) per patient.